ABIO ARCA biopharma Inc.

NewsSee all news

1. 18 February 2020 ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update

   U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation anticipated fourth quarter of 2020Trial to

2. 06 November 2019 ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update

   PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies WESTMINSTER,

3. 12 September 2019 ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium

   WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for

4. 11 September 2019 Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting

   WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for